글로벌 바이오제약 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

생물제약 시장 분석

생물약품 시장은 혁신적인 치료법에 대한 수요 증가와 생명공학의 발전으로 인해 상당한 성장을 경험했습니다. 생물학적 공급원에서 파생된 생물약품에는 단일클론 항체 , 백신, 재조합 단백질과 같은 광범위한 제품이 포함되며, 이는 암, 자가면역 질환, 감염성 질환을 포함한 다양한 질병을 치료하는 데 도움이 됩니다. 만성 질환의 유병률 증가와 개인 맞춤 의학 에 대한 필요성은 시장 확장을 더욱 촉진했습니다. 첨단 유전자 치료법의 도입과 약물 개발 프로세스에 인공 지능을 통합하는 것과 같은 최근의 발전은 생물약품의 효율성과 효과를 향상시켰습니다. 또한 지원 규제 프레임워크와 연구 개발에 대한 투자 증가로 이 부문의 혁신이 촉진될 것으로 예상됩니다. 결과적으로 생물약품 시장은 지속적인 성장을 이룰 준비가 되어 있으며, 새로운 치료 옵션을 제공하고 전 세계적으로 환자 결과를 개선할 것입니다.

생물제약 시장 규모

글로벌 바이오제약 시장 규모는 2023년에 10억 2천만 달러로 평가되었으며, 2031년까지 26억 2천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 6%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

생물제약 시장 동향

“표적 치료에 대한 수요 증가 ”

바이오제약 시장은 기술의 발전과 표적 치료에 대한 수요 증가에 힘입어 빠르게 진화하고 있습니다. 개인화된 의학 및 생물학적 제제를 포함한 약물 개발 프로세스의 혁신은 다양한 질병에 대한 치료 환경을 재편하고 있습니다. 주목할 만한 추세 중 하나는 암 및 자가면역 질환과 같은 질환을 치료하는 데 효과가 있는 것으로 입증된 단일클론 항체의 사용이 증가하고 있다는 것입니다. 이러한 엔지니어링된 단백질은 질병 경로를 정밀하게 타겟팅하여 효능을 개선하고 부작용을 줄입니다. 게다가 바이오시밀러의 부상은 시장에서 경쟁과 접근성을 강화하여 비용 효율적인 치료 옵션을 제공합니다. 전반적으로 이러한 추세는 바이오제약 부문의 지속적인 변화를 강조하여 보다 효과적이고 맞춤화된 치료 솔루션을 위한 길을 열었습니다.

보고서 범위 및 바이오제약 시장 세분화

Biopharmaceuticals Market Definition

Biopharmaceuticals are medicinal products produced using biotechnology, involving biological sources such as living cells and organisms. Unlike traditional pharmaceuticals, which are often chemically synthesized, biopharmaceuticals are typically large, complex molecules, including proteins, nucleic acids, or carbohydrates. They are designed to target specific diseases or conditions, often offering more effective and personalized treatment options. For instance biopharmaceuticals include monoclonal antibodies, vaccines, and recombinant proteins used in the treatment of various diseases, including cancer, diabetes, and autoimmune disorders. The development of biopharmaceuticals involves advanced techniques such as genetic engineering and recombinant DNA technology, leading to innovative therapies that have revolutionized the treatment landscape in modern medicine.

Biopharmaceuticals Market Dynamics

Drivers

• Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic illnesses, including cancer, diabetes, and autoimmune disorders, has significantly fueled the demand for effective therapeutic options, thereby driving the growth of the biopharmaceuticals market. As these conditions become more widespread, patients require innovative treatments that offer better efficacy and safety profiles than traditional therapies. Biopharmaceuticals, such as monoclonal antibodies and targeted therapies, are specifically designed to address the complexities of these chronic diseases by targeting specific biological pathways. This tailored approach improves patient outcomes and enhances the quality of life for those affected. Moreover, the ongoing advancements in biotechnology enable the continuous development of new biopharmaceuticals that can provide effective solutions for these chronic conditions, solidifying their importance in modern healthcare and contributing to the overall growth of the market.

• Increasing Awareness and Adoption

The growing awareness among healthcare professionals and patients regarding the benefits of biopharmaceutical therapies significantly contributes to their acceptance and utilization in clinical settings. As education and information dissemination improve, medical practitioners are increasingly recognizing the efficacy and potential of biopharmaceuticals in treating various diseases, particularly chronic and complex conditions. Patients, informed by healthcare providers and advocacy groups, are also more willing to explore these advanced therapeutic options, leading to increased demand. This heightened understanding encourages healthcare systems to integrate biopharmaceutical therapies into treatment protocols, further driving market growth.

Opportunities

• Expansion of Biosimilars

The growing acceptance and regulatory approval of biosimilars represent a substantial opportunity for biopharmaceutical market players to provide cost-effective alternatives to existing branded medications. Biosimilars, which are highly similar to already approved biologic products, offer comparable efficacy and safety profiles, allowing healthcare providers to choose more affordable treatment options for patients. This is particularly significant in the context of rising healthcare costs and the need for accessible treatments, especially for chronic conditions such as cancer and autoimmune diseases. As healthcare systems worldwide strive to manage expenses while maintaining high-quality care, the demand for biosimilars is expected to increase. Consequently, companies that invest in the development and marketing of biosimilars can enhance patient access to essential medications while capitalizing on this lucrative market segment, driving overall growth in the biopharmaceuticals industry.

• Technological Advancements in Biotechnology

Innovations in biotechnology, particularly advancements like CRISPR gene editing and cutting-edge manufacturing techniques, are significantly reshaping the biopharmaceutical landscape. CRISPR technology allows for precise modifications in the genetic material of organisms, facilitating the development of targeted therapies and novel drug candidates for various diseases, including genetic disorders and cancers. In addition, improvements in manufacturing processes, such as continuous bioprocessing and single-use technologies, enhance the efficiency and scalability of biopharmaceutical production. These innovations reduce production costs and shorten development timelines, allowing companies to bring therapies to market more quickly. As the demand for innovative and effective treatments grows, leveraging these biotechnological advancements presents a valuable opportunity for market players to enhance their product offerings and strengthen their competitive positions within the biopharmaceutical industry.

Restraints/Challenges

• Shortage of Skilled Professionals

The biopharmaceutical industry is currently facing a significant challenge due to a shortage of skilled professionals in biotechnology and related fields. This lack of expertise hampers innovation and development efforts, as organizations struggle to recruit and retain qualified scientists, researchers, and technicians necessary for advancing biopharmaceutical research and production. The complex nature of biopharmaceutical development requires specialized knowledge in areas such as molecular biology, biochemistry, and regulatory affairs. As a result, companies may experience delays in bringing new therapies to market, reducing their competitive edge in a rapidly evolving industry. Furthermore, the shortage of skilled workers can lead to increased operational costs and limited capacity for research and development initiatives.

• High Production Costs

The manufacturing processes involved in biopharmaceuticals are inherently complex and costly, necessitating specialized facilities, advanced technology, and stringent quality controls. These high production costs can pose significant challenges for biopharmaceutical companies, as they may struggle to set competitive prices for their products. As a result, the affordability and accessibility of essential medications can be compromised, limiting patient access to innovative therapies. Smaller companies, in particular, may find it difficult to bear these expenses, which can inhibit their ability to bring new products to market. In addition, the economic burden of high production costs can lead to reduced investment in research and development, ultimately stifling innovation within the industry.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Biopharmaceuticals Market Scope

The market is segmented on the basis of product type, service, raw material type, and application. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Monoclonal Antibodies
• Recombinant Growth Factors
• Purified Proteins
• Recombinant Proteins
• Recombinant Hormones
• Vaccines
• Synthetic Immunomodulatory Agents
• Other

Service

• Laboratory Testing
• Custom Testing / Customer Proprietary Testing
• Compendial Testing
• Multi-Compendial Laboratory Testing

Raw Material Type

• Formulation Excipients
• Active Pharmaceutical Ingredients (API)
• Compendial Methods (USP / EP / JP) Based Vendor Qualification Program Support

Application

• Oncology
• Inflammatory and Infectious Diseases
• Autoimmune Disorders
• Metabolic Disorders
• Hormonal Disorders
• Cardiovascular Diseases
• Neurological Diseases
• Other

Biopharmaceuticals Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product type, service, raw material type, and application as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the global biopharmaceuticals market, driven by a robust network of healthcare facilities and cutting-edge treatment options. This region excels in delivering therapies that target the root causes of complex diseases, resulting in better therapeutic outcomes. Consequently, the enhanced quality of patient care in North America reinforces its dominant position in the biopharmaceutical sector.

Asia-Pacific is projected to experience substantial growth from 2024 to 2031, fueled by heightened government initiatives aimed at raising awareness and promoting health advancements. The region is also benefiting from rapid technological innovations that enhance healthcare delivery and accessibility. In addition, the increasing demand for high-quality healthcare services among the population further contributes to the region's robust market expansion.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Biopharmaceuticals Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Biopharmaceuticals Market Leaders Operating in the Market Are:

• Amgen Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• Johnson & Johnson Private Limited (U.S.)
• Sanofi (France)
• Abbott (U.S.)
• AstraZeneca (U.K.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• BIOMÉRIEUX (France)
• Novartis AG (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• Novo Nordisk A/S (Denmark)
• Merck & Co., Inc. (U.S.)
• GSK Plc (U.K.)
• Biogen (U.S.)
• Bayer AG (Germany)
• Pfizer Inc. (U.S.)

Latest Developments in Biopharmaceuticals Market

• In March 2023, F. Hoffmann-La Roche Ltd partnered with Eli Lilly and Company to advance the development of Roche’s Elecsys Amyloid Plasma Panel (EAPP). This cutting-edge blood test is designed to enhance the early diagnosis of Alzheimer’s disease, offering potential improvements in patient outcomes. The collaboration highlights both companies' commitment to innovation in Alzheimer's detection and treatment
• In August 2022, AstraZeneca's Evusheld, a long-acting antibody combination comprising tixagevimab and cilgavimab (previously known as AZD7442), has been approved by Japan’s Ministry of Health, Labour and Welfare (MHLW). This therapy is indicated for both the prevention and treatment of symptomatic disease resulting from SARS-CoV-2 infection. The approval highlights AstraZeneca's ongoing efforts to provide effective therapeutic options in the fight against COVID-19
• In February 2022, Johnson & Johnson Services, Inc. received approval from the U.S. FDA for CARVYKTI, a groundbreaking CAR-T therapy specifically designed for the treatment of refractory multiple myeloma in adults. This innovative therapy offers new hope for patients who have not responded to prior treatments, showcasing advancements in personalized medicine for cancer care. The approval underscores Johnson & Johnson's commitment to developing effective solutions for complex hematological conditions
• In February 2021, Bristol Myers Squibb entered into a definitive agreement with The Rockefeller University, acquiring a worldwide exclusive license to develop, manufacture, and market a novel monoclonal antibody duo for COVID-19 therapy and prevention. This innovative treatment leverages two monoclonal antibodies designed to target and neutralize the SARS-CoV-2 virus by blocking its spike protein. The collaboration underscores Bristol Myers Squibb's commitment to advancing therapeutic solutions against COVID-19 through cutting-edge antibody technology
• 2021년 2월, AbbVie는 Caribou Biosciences, Inc.와 키메라 항원 수용체(CAR) T 세포 치료제의 연구 개발에 초점을 맞춘 라이선스 계약을 체결하여 파트너십을 맺었습니다. 이 협력은 Caribou의 혁신적인 유전자 편집 기술을 활용하여 암 치료를 위한 CAR T 세포 치료제의 효능과 안전성을 향상시키는 것을 목표로 합니다. 이 계약은 두 회사가 면역 종양학 분야에서 획기적인 치료적 접근 방식을 발전시키려는 의지를 반영합니다.

SKU-23925